阿托伐他汀对阵发性房颤患者超敏C反应蛋白水平及发作的影响(2)
[3] Chouhan UM， Chakrabarti S， Millward LJ. Simvastatin interaction with clarithromycin and amiodarone causing myositis. Ann Pharmacother， 2005， 39: 1760-1761.
[4] Cardin S， Li D， Thorin-Trescases N， et al. Evolution of the atrial fibrillation substrate in experimental congestive heart failure: angiotensin-dependent and -independent pathways. Cardiovasc Res， 2003， 60:315-325.
[5] Saksena S， Hettrick DA， Koehler JL， et al. Progression of paroxysmal atrial fibrillation to persistent atrial fibrillation in patients with bradyarrhythmias. Am Heart J， 2007， 154: 884-892.
[6] Lo B， Fijnheer R， Nierich AP， et al. C-reactive protein is a risk indicator for atrial fibrillation after myocardial revascularization. Ann Thorac Surg， 2005， 79: 1530-1535
[7] Acevedo M， Corbalán R， Braun S， et al. C-reactive protein and atrial fibrillation: “evidence for the presence of inflammation in the perpetuation of the arrhythmia”. Int J Cardiol， 2006， 108:326-331.
[8] Hohnloser SH， Li YG， Bender B， et al. Pharmacological management of atrial fibrillation: an update. J Cardiovasc Pharmacol Ther， 2000， 5:11-16.
[9] Daoud EG.. Percutaneous catheter ablation of atrial fibrillation. Expert Rev Cardiovasc Ther， 2007， 5:693-705.
[10] DiNapoli M， Papa F. Angiotensin-converting enzyme inhibitor use is associated with reduced plasma concentration of C-reactive protein in patients with first-ever ischemic stroke. Stroke， 2003， 34: 2922-2929., 百拇医药(陈 俊)
[4] Cardin S， Li D， Thorin-Trescases N， et al. Evolution of the atrial fibrillation substrate in experimental congestive heart failure: angiotensin-dependent and -independent pathways. Cardiovasc Res， 2003， 60:315-325.
[5] Saksena S， Hettrick DA， Koehler JL， et al. Progression of paroxysmal atrial fibrillation to persistent atrial fibrillation in patients with bradyarrhythmias. Am Heart J， 2007， 154: 884-892.
[6] Lo B， Fijnheer R， Nierich AP， et al. C-reactive protein is a risk indicator for atrial fibrillation after myocardial revascularization. Ann Thorac Surg， 2005， 79: 1530-1535
[7] Acevedo M， Corbalán R， Braun S， et al. C-reactive protein and atrial fibrillation: “evidence for the presence of inflammation in the perpetuation of the arrhythmia”. Int J Cardiol， 2006， 108:326-331.
[8] Hohnloser SH， Li YG， Bender B， et al. Pharmacological management of atrial fibrillation: an update. J Cardiovasc Pharmacol Ther， 2000， 5:11-16.
[9] Daoud EG.. Percutaneous catheter ablation of atrial fibrillation. Expert Rev Cardiovasc Ther， 2007， 5:693-705.
[10] DiNapoli M， Papa F. Angiotensin-converting enzyme inhibitor use is associated with reduced plasma concentration of C-reactive protein in patients with first-ever ischemic stroke. Stroke， 2003， 34: 2922-2929., 百拇医药(陈 俊)